Αρχική World News Inavolisib Plus Palbociclib-Fulvestrant Prolongs OS in Patients with PIK3CA-Mutated Advanced Breast Cancer World News Inavolisib Plus Palbociclib-Fulvestrant Prolongs OS in Patients with PIK3CA-Mutated Advanced Breast Cancer Από Ogkologos - 30 Ιουνίου, 2025 641 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the INAVO120 study Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ Ahead of the Special European Council Meeting on 26-27 November, ESMO Calls on EU Governments to Continue Support for the Cancer Mission European Parliament backs key priorities advocated by ESMO for cancer research and innovation FDA approves giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer MOST POPULAR Some Children with Wilms Tumor Can Receive Less Therapy, Study Suggests 23 Μαΐου, 2018 Dear Prime Minister: “Please don’t delay action again, we’re counting on... 16 Οκτωβρίου, 2020 Genetic Risk Score Increases Prediction of Severe Obesity in Adult Survivors... 5 Αυγούστου, 2022 Ensartinib Improves DFS Outcomes in Patients with ALK-positive, Completely Resected Stage II... 27 Ιουλίου, 2026 Φόρτωση περισσοτέρων HOT NEWS FDA Grants Accelerated Approval to Naxitamab for High-Risk Neuroblastoma in Bone... ESMO Welcomes the European Commission’s Life Sciences Strategy: A Vital Step... ‘Scandinavian quality and Singaporean efficiency’: what the autumn statement means for... Speaking with One Cancer Voice for cancer patients in England